

IFW



PATENT
CASE CN06055US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of: :
Bernard R. Neustadt et al :
:
For Patent For: Examiner: To be assigned
2-Alkynyl- and 2-Alkenyl-Pyrazolo-[4,3-e]- :
1,2,4-Triazolo-[1,5-c]-Pyrimidine :
Adenosine A_{2a} Receptor Antagonists : Art Unit: To be assigned
Serial No.: 10/829,416 :
Filing Date: April 21, 2004 :
-----X

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98.
Applicants enclose a Form PTO-1449 (one page) listing publications known
to applicants that may be relevant to this application.

This Statement is being filed within three months of filing the application.

All publications or equivalents thereto were cited in the specification.
Publication AP is the published PCT application corresponding to
PCT/US02/32630, and AB is the as-yet unpublished US equivalent to
PCT/US03/40456.


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C., 20231, on <u>June 7, 2004</u>	
<u>Anita W. Magatti</u>	
Registered Representative	
<u></u>	<u>6/7/04</u>
Signature	Date

BA and BB replace the incorrect reference to the *Brain Research* publication cited on page 100, lines 5-6.

Copies of the cited publications are enclosed.

The examiner is respectfully requested to examine the publications, initial the form PTO-1449 and return a copy of the initialed form to applicants.

Respectfully submitted,



Anita W. Magatti
Reg. No. 29,825
Attorney for Applicants
(908) 298-5067

Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CN06055US01		SERIAL NO.: 10/829,416	
INFORMATION DISCLOSURE STATEMENT FOR PATENT (Use several sheets if necessary)				APPLICANT: Bernard R. Neustadt et al			
				FILING DATE: 4/21/04		GROUP: To be assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,565,460	10/15/96	Suzuki et al	514		
	AB	10/738,906	12/17/03 (filed)	Grezlak et al			
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 95/01356	1/12/95	WIPO	C07D		X
	AM	WO 97/05138	2/13/97	WIPO	C07D		X
	AN	WO98/52568	11/26/98	WIPO	A61K		X
	AO	WO 01/92264	12/6/01	WIPO	C07D		X
	AP	WO 03/032996	4/24/03	WIPO	A61K		X
	AQ	WO 02/055083	7/18/02	WIPO	A61K		X
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	Baraldi et al, <u>J. Med. Chem.</u> , <u>39</u> (1996), 1164-1171.					
	AS	Huang et al, <u>Tet. Lett.</u> , <u>40</u> (1999), 8647-8650.					
	AT	Varelis et al, <u>Aust. J. Chem.</u> , <u>48</u> (1995), 1775-1779.					
	AU	Kanth et al, <u>J. Org. Chem.</u> , <u>56</u> (1991), 5964-5965.					
	AV	Orito et al, <u>Synthesis</u> , <u>23</u> (1997), 23-25.					
	AW	Aiba et al, <u>Bioorg. Med. Chem. Lett.</u> , <u>11</u> (2001), 2783-2786.					
	AX	Baum et al, <u>J. Org. Chem.</u> , <u>48</u> (1983), 2953-2956.					
	AY	Cornelius et al, <u>Synth. Comm.</u> , <u>24</u> , (19) (1994), 2777-2788.					
	AZ	Lee et al, <u>Synth. Comm.</u> , <u>33</u> , (9) (2003), 1611-1614.					
	BA	Ungerstedt et al, <u>Brain Research</u> , <u>24</u> (1970), 485-493.					
	BB	Ungerstedt, <u>Eur. J. Pharmacol.</u> , <u>5</u> (1968), 107-110.					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							